Health care continues to be the top issue for most Canadians who want assurances from political leaders that they will have access to quality health care when they need it. Health care officials and politicians across the country are challenged by the sustainability problem: how to pay for quality universal health care when costs are rising, and other social programs require funding.
At the same time, governments are challenged to provide the policy and regulatory environments for the components of health care given finite resources and pressures to improve service. Increasingly, the private sector is being seen as a partner in policy development, but this requires a fine balance between public and private interests and participation that is clear, transparent and accountable.
Given the multi-jurisdictional nature of health policy and innovation across Canada, Global’s Health & Life Sciences team regularly draws upon our consultants from across Canada to provide a national or province-specific suite of services. The Health & Life Sciences team monitors, advocates, and provides strategic and tactical advice on the following issues:
- Regulatory issues, including the health product approval process and Food and Drugs Actmodernization
- Public reimbursement policies and trends
- Intellectual property issues (e.g., patent policies)
- Federal/Provincial/Territorial initiatives, including the Canadian Agency for Drugs and Technologies in Health (CADTH) and Common Drug Review (CDR)
- Industrial incentive policy and marketing practice regulations
- Monitoring federal and provincial parliamentary committees and political initiatives
Global’s Health & Life Sciences team serves international innovative pharmaceutical companies, medical device manufacturers, health associations, non-profit health organizations and health care product manufacturers.